SEI Investments
ARQT icon

SEI Investments’s Arcutis Biotherapeutics ARQT Stock Holding History

SEI Investments’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.86M Buy
206,141
+101,855
+98% +$2.6M ﹤0.01% 1552
2025
Q4 		$3.03M Buy
104,286
+78,423
+303% +$2.01M ﹤0.01% 1649
2025
Q3 		$488K Buy
25,863
+13,764
+114% +$217K ﹤0.01% 2242
2025
Q2 		$170K Sell
12,099
-27,251
-69% -$382K ﹤0.01% 2598
2025
Q1 		$615K Buy
+39,350
New +$554K ﹤0.01% 2076
2023
Q2 		– Sell
-273,599
Closed -$3.01M – 2672
2023
Q1 		$3.01M Buy
+273,599
New +$3.96M 0.01% 1432
2022
Q4 		– Sell
-172,848
Closed -$3.3M – 2531
2022
Q3 		$3.3M Buy
172,848
+28,910
+20% +$655K 0.01% 1294
2022
Q2 		$3.07M Buy
+143,938
New +$2.95M 0.01% 1349

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return